Officials with the Indianapolis Public Schools recently announced that the district will receive more than $10 million from ...

Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

The Eli Lilly and Company Foundation awarded a multi-year grant of up to $5.5 million to the Indianapolis Public Schools (IPS ...

The IPS Foundation has received a $5.5 million grant from the Eli Lilly Foundation to support Destination 2032, a new initiative aimed at enhancing STEM education for IPS students.

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major competitor in China.

Shares of Eli Lilly & Co. LLY slid 2.47% to $775.45 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.52% to 6,173.07 ...

As the weight loss treatment space reaches a new saturation point, Novo Nordisk, Eli Lilly and their closest—but still distant—competitors continue to vie for a greater share of the ever- expanding ...

Meanwhile, Lilly is notching win after win. Eli Lilly's position in the weight management market makes its stock attractive, considering how fast this area is projected to grow in the coming years.

Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics marks a strategic expansion into cardiovascular genetic medicine. The pharmaceutical giant paid a premium of about 113% over Verve’s ...

Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination therapy might change that.

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.